Wei Wang

List of Publications by Year
in descending order

38 papers	2,257 citations	394421 19 h-index	302126 39 g-index
42 all docs	42 docs citations	42 times ranked	3317 citing authors

#	Article	IF	Citations
1	Hepatocyte Growth Factor Induces Gefitinib Resistance of Lung Adenocarcinoma with Epidermal Growth Factor Receptorâ€“Activating Mutations. Cancer Research, 2008, 68, 9479-9487.	0.9	574
2	Crosstalk to Stromal Fibroblasts Induces Resistance of Lung Cancer to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors. Clinical Cancer Research, 2009, 15, 6630-6638.	7.0	255
3	EGFR-TKI resistance promotes immune escape in lung cancer via increased PD-L1 expression. Molecular Cancer, 2019, 18, 165.	19.2	160
4	MiRâ€200c inhibits autophagy and enhances radiosensitivity in breast cancer cells by targeting UBQLN1. International Journal of Cancer, 2015, 136, 1003-1012.	5.1	107
5	Transient PI3K Inhibition Induces Apoptosis and Overcomes HGF-Mediated Resistance to EGFR-TKIs in EGFR Mutant Lung Cancer. Clinical Cancer Research, 2011, 17, 2260-2269.	7.0	101
6	MiR-20a Induces Cell Radioresistance by Activating the PTEN/PI3K/Akt Signaling Pathway in Hepatocellular Carcinoma. International Journal of Radiation Oncology Biology Physics, 2015, 92, 1132-1140.	0.8	95
7	Hepatocyte Growth Factor Reduces Susceptibility to an Irreversible Epidermal Growth Factor Receptor Inhibitor in EGFR-T790M Mutant Lung Cancer. Clinical Cancer Research, 2010, 16, 174-183.	7.0	93
8	Met Kinase Inhibitor E7050 Reverses Three Different Mechanisms of Hepatocyte Growth Factorâ€“Induced Tyrosine Kinase Inhibitor Resistance in EGFR Mutant Lung Cancer. Clinical Cancer Research, 2012, 18, 1663-1671.	7.0	81
9	The Therapeutic Efficacy of Antiâ€“Vascular Endothelial Growth Factor Antibody, Bevacizumab, and Pemetrexed against Orthotopically Implanted Human Pleural Mesothelioma Cells in Severe Combined Immunodeficient Mice. Clinical Cancer Research, 2007, 13, 5918-5925.	7.0	69
10	Transient IGF-1R inhibition combined with osimertinib eradicates AXL-low expressing EGFR mutated lung cancer. Nature Communications, 2020, 11, 4607.	12.8	69
11	Dual PI3K/mTOR Inhibitors, GSK2126458 and PKI-587, Suppress Tumor Progression and Increase Radiosensitivity in Nasopharyngeal Carcinoma. Molecular Cancer Therapeutics, 2015, 14, 429-439.	4.1	63
12	HM1.24 (CD317) is a novel target against lung cancer for immunotherapy using anti-HM1.24 antibody. Cancer Immunology, Immunotherapy, 2009, 58, 967-976.	4.2	57
13	E7080, a Multiâ€“Tyrosine Kinase Inhibitor, Suppresses the Progression of Malignant Pleural Mesothelioma with Different Proangiogenic Cytokine Production Profiles. Clinical Cancer Research, 2009, 15, 7229-7237.	7.0	55
14	Dual Inhibition of Met Kinase and Angiogenesis to Overcome HGF-Induced EGFR-TKI Resistance in EGFR Mutant Lung Cancer. American Journal of Pathology, 2012, 181, 1034-1043.	3.8	55
15	Pleural Mesothelioma Instigates Tumor-Associated Fibroblasts To Promote Progression via a Malignant Cytokine Network. American Journal of Pathology, 2011, 179, 1483-1493.	3.8	54
16	Hypoxia-Responsive Mir-301a and Mir-301b Promote Radioresistance of Prostate Cancer Cells via Downregulating NDRG2. Medical Science Monitor, 2016, 22, 2126-2132.	1.1	52
17	MET Copy Number Gain Is Associated with Gefitinib Resistance in Leptomeningeal Carcinomatosis of EGFR-mutant Lung Cancer. Molecular Cancer Therapeutics, 2017, 16, 506-515.	4.1	52
18	The EGFR Ligands Amphiregulin and Heparin-Binding EGF-like Growth Factor Promote Peritoneal Carcinomatosis in CXCR4-Expressing Gastric Cancer. Clinical Cancer Research, 2011, 17, 3619-3630.	7.0	46

#	Article	IF	Citations
19	Genetically engineered humanized antiâ€ganglioside GM2 antibody against multiple organ metastasis produced by GM2â€expressing smallâ€cell lung cancer cells. Cancer Science, 2011, 102, 2157-2163.	3.9	31
20	Chimeric and humanized anti-HM1.24 antibodies mediate antibody-dependent cellular cytotoxicity against lung cancer cells. Lung Cancer, 2009, 63, 23-31.	2.0	17
21	Impact of molecular subtypes on metastatic behavior and overall survival in patients with metastatic breast cancer: A singleâ€center study combined with a large cohort study based on the Surveillance, Epidemiology and End Results database. Oncology Letters, 2020, 20, 1-1.	1.8	15
22	E7080 Suppresses Hematogenous Multiple Organ Metastases of Lung Cancer Cells with Nonmutated Epidermal Growth Factor Receptor. Molecular Cancer Therapeutics, 2011, 10, 1218-1228.	4.1	14
23	MET inhibitor PHA-665752 suppresses the hepatocyte growth factor-induced cell proliferation and radioresistance in nasopharyngeal carcinoma cells. Biochemical and Biophysical Research Communications, 2014, 449, 49-54.	2.1	14
24	Abnormal amphiregulin expression correlates with gastric cancer prognosis. Oncotarget, 2016, 7, 76684-76692.	1.8	14
25	Inhibition of NFâ€ºB improves sensitivity to irradiation and EGFRâ€TKIs and decreases irradiationâ€induced lung toxicity. International Journal of Cancer, 2019, 144, 200-209.	5.1	13
26	Tumour-associated macrophages heterogeneity drives resistance to clinical therapy. Expert Reviews in Molecular Medicine, 2022, 24, e17.	3.9	12
27	Periostin: a putative mediator involved in tumour resistance to anti-angiogenic therapy?. Cell Biology International, 2011, 35, 1085-1088.	3.0	9
28	Therapeutic activity of glycoengineered antiâ€‹<scp>GM</scp>2 antibodies against malignant pleural mesothelioma. Cancer Science, 2015, 106, 102-107.	3.9	9
29	Hepatocyte growth factor reduces sensitivity to the epidermal growth factor receptor-tyrosine kinase inhibitor, gefitinib, in lung adenocarcinoma cells harboring wild-type EGFR. Oncotarget, 2016, 7, 16273-16281.	1.8	9
30	Dual inhibition of VEGF and PARP suppresses KRAS-mutant colorectal cancer. Neoplasia, 2020, 22, 365-375.	5.3	7
31	Reduced PHLPP Expression Leads to EGFR-TKI Resistance in Lung Cancer by Activating PI3K-AKT and MAPK-ERK Dual Signaling. Frontiers in Oncology, 2021, 11, 665045.	2.8	7
32	Antiangiogenic therapies for malignant pleural mesothelioma. Frontiers in Bioscience - Landmark, 2011, 16, 740.	3.0	6
33	High PHLPP1 expression levels predicts longer time of acquired resistance to EGFR tyrosine kinase inhibitors in patients with lung adenocarcinoma. Oncotarget, 2017, 8, 59000-59007.	1.8	6
34	Prognostic value of several biomarkers for the patients with malignant pleural mesothelioma. Tumor Biology, 2015, 36, 7375-7384.	1.8	5
35	Prognostic values, ceRNA network, and immune regulation function of SDPR in KRAS-mutant lung cancer. Cancer Cell International, 2021, 21, 49.	4.1	5
36	Targeted therapies for RET-fusion cancer: Dilemmas and breakthrough. Biomedicine and Pharmacotherapy, 2020, 132, 110901.	5.6	2

#	Article	IF	Citations
37	HGF-MET in Resistance to EGFR Tyrosine Kinase Inhibitors in Lung Cancer. Current Signal Transduction Therapy, 2011, 6, 228-233.	0.5	2
38	Cancer mutation profiles predict ICIs efficacy in patients with non-small cell lung cancer. Expert Reviews in Molecular Medicine, 2022, 24, e16.	3.9	1